계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
EnClear Therapies
company
About
EnClear Therapies is a biotechnology company developing device-based therapies for the treatment of neurodegenerative disease
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $10M
- Industries
- Biotechnology,Therapeutics
- Founded date
- Jan 1, 2018
- Number Of Employee
- 1 - 10
- Operating Status
- Active
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$12M
EnClear Therapies has raised a total of
$12M
in funding over 2 rounds. Their latest funding was raised on
Feb 19, 2020 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 19, 2020 | Series A | $10M | 1 | — | — | Detail |
| Mar 14, 2019 | Seed | $2M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
EnClear Therapies is funded by 2 investors.
Global health sciences venture fund
and Sanford Biosciences
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
|
|
— | Seed |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
